---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-032413"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2021-12-23T23:59:59+00:00"
generated_at: "2026-06-27T22:46:40.561364+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Oncotelic Therapeutics dismisses Baker Tilly, hires Rose Snyder & Jacobs as auditor

## Summary
- Baker Tilly's reports for FY 2020 and 2019 contained a going-concern emphasis paragraph.
- No disagreements or reportable events occurred with Baker Tilly during the relevant periods.
- New auditor RSJ was engaged effective December 21, 2021 for FY 2021 audit.
- Company did not consult RSJ on any accounting or auditing matters prior to engagement.

## SEC filing metadata
- accession: 0001493152-21-032413
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2021-12-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 4.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315221032413/0001493152-21-032413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315221032413/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-032413
- JSON: https://secwatch.observer/filing/0001493152-21-032413.json
- Plain text: https://secwatch.observer/filing/0001493152-21-032413.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.